• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.关注“B”之后的“T”：为未来的大流行塑造疫苗。
PLoS Biol. 2023 Nov 7;21(11):e3002351. doi: 10.1371/journal.pbio.3002351. eCollection 2023 Nov.
2
Vaccines against SARS-CoV-2 variants and future pandemics.针对 SARS-CoV-2 变体和未来大流行的疫苗。
Expert Rev Vaccines. 2022 Oct;21(10):1363-1376. doi: 10.1080/14760584.2022.2110075. Epub 2022 Aug 12.
3
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
4
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.基于基因的疫苗平台在应对 COVID-19 大流行方面的进展。
Adv Drug Deliv Rev. 2021 Mar;170:113-141. doi: 10.1016/j.addr.2021.01.003. Epub 2021 Jan 7.
5
Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy.通过基于证据的快速跟踪策略，重新审视印度在大流行期间加速疫苗开发的监管框架。
Indian J Med Res. 2020;152(1 & 2):156-163. doi: 10.4103/ijmr.IJMR_3640_20.
6
Heterologous immunity induced by 1 generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine.由 1 代 COVID-19 疫苗诱导的异源免疫及其在开发泛冠状病毒疫苗中的作用。
Front Immunol. 2022 Aug 15;13:952229. doi: 10.3389/fimmu.2022.952229. eCollection 2022.
7
Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic.开发针对 SARS-CoV-2 的树突状细胞疫苗：大流行中的突破。
Front Immunol. 2022 Sep 6;13:989685. doi: 10.3389/fimmu.2022.989685. eCollection 2022.
8
[SARS-CoV-2 vaccines].[严重急性呼吸综合征冠状病毒2型疫苗]
Ugeskr Laeger. 2021 Mar 8;183(10).
9
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发：近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
10
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.宿主对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的保护性免疫与 COVID-19 疫苗诱导的对 SARS-CoV-2 及其变体的免疫。
Viruses. 2022 Nov 17;14(11):2541. doi: 10.3390/v14112541.

本文引用的文献

1
Erratum for the Review "Insights into dengue immunity from vaccine trials".《疫苗试验对登革热免疫的见解》综述勘误
Sci Transl Med. 2023 Aug 16;15(709):eadk1254. doi: 10.1126/scitranslmed.adk1254.
2
Humoral and cellular immune memory to four COVID-19 vaccines.体液免疫和细胞免疫对四种 COVID-19 疫苗的记忆。
Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27.
3
Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore.新加坡 2019 年冠状病毒病感染和重症的 mRNA 疫苗和全病毒灭活疫苗的疗效比较。
Clin Infect Dis. 2022 Oct 12;75(8):1442-1445. doi: 10.1093/cid/ciac288.
4
Understanding T cell responses to COVID-19 is essential for informing public health strategies.了解针对 COVID-19 的 T 细胞反应对于制定公共卫生策略至关重要。
Sci Immunol. 2022 May 20;7(71):eabo1303. doi: 10.1126/sciimmunol.abo1303.
5
CEPI launches 100-day vaccine "moonshot".流行病防范创新联盟启动百日疫苗“登月计划”。
Lancet. 2022 Mar 19;399(10330):1107-1108. doi: 10.1016/S0140-6736(22)00513-X.
6
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.预先存在的聚合酶特异性 T 细胞在 SARS-CoV-2 无血清学阴性中扩增。
Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10.
7
Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.从接种疫苗和自然感染个体的全血中快速测量 SARS-CoV-2 刺突 T 细胞。
J Clin Invest. 2021 Sep 1;131(17). doi: 10.1172/JCI152379.
8
Systems vaccinology of the BNT162b2 mRNA vaccine in humans.人体中 BNT162b2 mRNA 疫苗的系统疫苗学。
Nature. 2021 Aug;596(7872):410-416. doi: 10.1038/s41586-021-03791-x. Epub 2021 Jul 12.
9
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.早期 T 细胞和结合抗体反应与 COVID-19 RNA 疫苗疗效的出现有关。
Med. 2021 Jun 11;2(6):682-688.e4. doi: 10.1016/j.medj.2021.04.003. Epub 2021 Apr 8.
10
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.在 COVID-19 患者中，功能性 SARS-CoV-2 特异性 T 细胞的早期诱导与快速病毒清除和轻症疾病相关。
Cell Rep. 2021 Feb 9;34(6):108728. doi: 10.1016/j.celrep.2021.108728. Epub 2021 Jan 21.

关注“B”之后的“T”：为未来的大流行塑造疫苗。

Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.

机构信息

Department of Infectious Diseases, Singapore General Hospital, Singapore.

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.

出版信息

PLoS Biol. 2023 Nov 7;21(11):e3002351. doi: 10.1371/journal.pbio.3002351. eCollection 2023 Nov.

DOI:10.1371/journal.pbio.3002351
PMID:37934720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10629617/
Abstract

The COVID-19 pandemic has accelerated the development of vaccines for viral infections. However, a failure to integrate T cell immunity as a determinant of vaccine efficacy could curtail advancement of newer vaccines for pandemic preparedness.

摘要

新冠疫情加速了针对病毒感染的疫苗研发。然而，如果不能将 T 细胞免疫作为疫苗有效性的决定因素纳入考量，那么新疫苗在大流行防范方面的进展将会受到限制。